Dyne Therapeutics Net Worth
Dyne Therapeutics Net Worth Breakdown | DYN |
Dyne Therapeutics Net Worth Analysis
Dyne Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dyne Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dyne Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dyne Therapeutics' net worth analysis. One common approach is to calculate Dyne Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dyne Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dyne Therapeutics' net worth. This approach calculates the present value of Dyne Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dyne Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dyne Therapeutics' net worth. This involves comparing Dyne Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dyne Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Dyne Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dyne Therapeutics' net worth research are outlined below:
| Dyne Therapeutics had very high historical volatility over the last 90 days | |
| Reported Net Loss for the year was (235.94 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne Therapeutics has about 291.84 M in cash with (188.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: Dyne, Avidity initiated at outperform by RBC on DM1 drugs |
Dyne Therapeutics Quarterly Good Will |
|
Dyne Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dyne Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dyne Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Dyne Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dyne Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dyne Therapeutics backward and forwards among themselves. Dyne Therapeutics' institutional investor refers to the entity that pools money to purchase Dyne Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tcg Crossover Management, Llc | 2024-09-30 | 2.7 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.4 M | Vr Adviser, Llc | 2024-09-30 | 2.2 M | Goldman Sachs Group Inc | 2024-06-30 | 2.1 M | Holocene Advisors, Lp | 2024-09-30 | 2 M | Geode Capital Management, Llc | 2024-09-30 | 1.9 M | Sofinnova Ventures | 2024-06-30 | 1.6 M | Artal Group S A | 2024-06-30 | 1.5 M | Jennison Associates Llc | 2024-09-30 | 1.3 M | Fmr Inc | 2024-09-30 | 9 M | Blackrock Inc | 2024-06-30 | 7.4 M |
Follow Dyne Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.17 B.Market Cap |
|
Project Dyne Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.43) | (1.36) | |
| Return On Capital Employed | (2.12) | (2.02) | |
| Return On Assets | (1.43) | (1.36) | |
| Return On Equity | (2.58) | (2.46) |
When accessing Dyne Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dyne Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dyne Therapeutics' profitability and make more informed investment decisions.
Evaluate Dyne Therapeutics' management efficiency
Dyne Therapeutics has Return on Asset of (0.4035) % which means that on every $100 spent on assets, it lost $0.4035. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6868) %, meaning that it generated no profit with money invested by stockholders. Dyne Therapeutics' management efficiency ratios could be used to measure how well Dyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to grow to -1.36. In addition to that, Return On Capital Employed is likely to grow to -2.02. As of the 29th of November 2024, Debt To Assets is likely to grow to 0.26, while Total Assets are likely to drop about 156.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.53 | 1.45 | |
| Tangible Book Value Per Share | 1.53 | 1.45 | |
| Enterprise Value Over EBITDA | (3.00) | (2.85) | |
| Price Book Value Ratio | 8.70 | 9.13 | |
| Enterprise Value Multiple | (3.00) | (2.85) | |
| Price Fair Value | 8.70 | 9.13 | |
| Enterprise Value | 699.6 M | 465.6 M |
The strategic vision of Dyne Therapeutics management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Return On Equity (0.69) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dyne Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dyne Therapeutics Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Dyne Therapeutics Earnings per Share Projection vs Actual
Dyne Therapeutics Corporate Management
| Romesh Subramanian | CoFounder Advisor | Profile | |
| Richard MBA | Senior Administration | Profile | |
| Ashish MBA | Chief Officer | Profile | |
| Oxana Beskrovnaya | Chief Officer | Profile | |
| Johanna FriedlNaderer | Chief Officer | Profile | |
| Lucia Celona | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.